Analyst Price Targets — DNTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 7:51 pm | Maury Raycroft | Jefferies | $98.00 | $79.23 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $98 at Jefferies |
| March 9, 2026 2:15 pm | Trevor Allred | Oppenheimer | $145.00 | $80.88 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $145 at Oppenheimer |
| March 9, 2026 2:14 pm | Alex Thompson | Stifel Nicolaus | $120.00 | $80.60 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $120 at Stifel |
| February 11, 2026 1:02 pm | — | Wedbush | $55.00 | $49.70 | TheFly | Dianthus price target raised to $55 from $46 at Wedbush |
| January 29, 2026 1:06 pm | — | UBS | $125.00 | $53.23 | TheFly | Dianthus price target raised to $125 from $62 at Oppenheimer |
| January 8, 2026 12:54 pm | — | Truist Financial | $63.00 | $38.09 | TheFly | Dianthus price target raised to $63 from $56 at Truist |
| November 6, 2025 2:26 pm | Trevor Allred | Oppenheimer | $62.00 | $36.46 | TheFly | Dianthus price target raised to $62 from $60 at Oppenheimer |
| October 14, 2025 10:08 am | Danielle Brill | Truist Financial | $56.00 | $34.42 | TheFly | Dianthus initiated with a Buy at Truist |
| September 8, 2025 4:14 pm | Yatin Suneja | Guggenheim | $100.00 | $31.73 | TheFly | Dianthus price target raised to $100 from $92 at Guggenheim |
| September 8, 2025 2:45 pm | Maury Raycroft | Jefferies | $51.00 | $31.80 | TheFly | Dianthus gMG data has positive read through to other indications, says Jefferies |
Latest News for DNTH
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) CAO Edward Carr sold 43,682 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a document filed with the Securities and Exchange Commission,
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) EVP Simrat Randhawa sold 33,830 shares of the firm's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. The transaction was disclosed in a legal filing with the Securities and Exchange Commission,
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a legal filing with the SEC, which
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it closed its previously announced underwritten public offering of 8,470,989 shares of its common stock,…
NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the pricing of its previously announced upsized underwritten public offering of 7,313,582 shares of its common stock…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DNTH.
U.S. House Trading
No House trades found for DNTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.